BiomX to Host Virtual Key Opinion Leader (KOL) Event to Review the Positive Results from Part 2 of Phase 1b/2a Trial of BX004 in Cystic Fibrosis Patients with Chronic Pseudomonas aeruginosa Infections on December 4, 2023
CAMBRIDGE, Mass. and NESS ZIONA, Israel, Nov. 30, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced it will host a virtual KOL Event on December 4, 2023 at 12:00 PM ET to discuss the positive topline results recently announced from Part 2 of Phase 1b/2a trial of BX004 in cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa (P. aeruginosa) infections. To register for the event, please click here.
The event will feature Dr. Eitan Kerem, M.D. (Hadassah University Medical Center) and Dr. Robert T. “Chip” Schooley, M.D. (University of California, San Diego), who will discuss phage therapy, the current treatment landscape, and the unmet medical need in cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa (P. aeruginosa) respiratory infections.
Jonathan Solomon, Chief Executive Officer of BiomX, will review topline results from Part 2 of the Phase 1b/2a trial evaluating the Company’s novel phage cocktail, BX004, as a potential treatment for chronic pulmonary infections caused by P. aeruginosa in CF patients.
BiomX is developing BX004, utilizing its proprietary BOLT platform, to address a significant unmet need facing thousands of CF patients who require new treatments to combat persistent and deadly lung infections. P. aeruginosa is a main contributor to morbidity and mortality in patients with CF.
A live question and answer session will follow the formal presentations.
About Dr. Eitan Kerem, M.D.
Professor Kerem’s interest in cystic fibrosis (CF) spans all aspects of the condition. He was involved in formulating the guidelines that paved the road to the standardization of CF care in Europe and other parts of the world. He has been a principal investigator in many national and international multicenter clinical trials in CF and is an author of key publications in this field.
Professor Kerem was Chairman of the Medical Advisory Board for the Israeli CF Foundation and served as a board member of the European Cystic Fibrosis Society (ECFS), initiating the development of the ECFS Patient Registry. He has been a member of numerous organizing committees for national and internatioal conferences, and was a president of the International Congress on Pediatric Pulmonology.
About Dr. Robert T. “Chip” Schooley, M.D.
His research interests include influenza, global health and international medicine, and the diagnosis and management of infections that cause death and morbidity in resource-limited settings. Dr. Schooley is particularly interested in the origin and development (pathogenesis) of HIV and HIV therapy, and was one of the first researchers to describe the humoral and cellular immune responses to HIV infection.
Dr. Schooley has developed a multidisciplinary research program for hepatitis C. He leads the Universidade Eduardo Mondlane-UC San Diego Medical Education Partnership Initiative and supervises postdoctoral fellows.
Prior to joining UC San Diego Health, Dr. Schooley was head of the Division of Infectious Diseases at University of Colorado and director of the Colorado Center for AIDS Research Virology Core Laboratory. During his tenure at Colorado, Dr. Schooley was chair of the National Institute of Allergy and Infectious Diseases' AIDS Clinical Trials Group. Before that, he served as associate professor of medicine at Harvard Medical School. Dr. Schooley is extensively published, having edited numerous books and authored hundreds of articles and book chapters. He serves on the editorial board of several medical journals, including Journal of Acquired Immune Deficiency Syndromes and Clinical Infectious Diseases.
Dr. Schooley completed fellowships in infectious diseases at the National Institute of Allergy and Infectious Diseases in Bethesda, Maryland, and at Massachusetts General Hospital in Boston. He earned his medical degree from Johns Hopkins University. Dr. Schooley is board certified in internal medicine. He is a fellow of the Infectious Disease Society of America and Royal Society of Medicine (UK), and member of numerous professional societies, including the American Society for Clinical Investigation, the Association of American Physicians, and the American Society of Tropical Medicine and Hygiene. In 2013, Dr. Schooley was honored with the Best Doctors in America and America's Top Doctors award.
Source: BiomX Inc.